Glynn Capital Management LLC Cuts Holdings in Merck & Co., Inc. $MRK

Glynn Capital Management LLC reduced its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 10.6% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 12,701 shares of the company’s stock after selling 1,500 shares during the period. Glynn Capital Management LLC’s holdings in Merck & Co., Inc. were worth $1,005,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in the stock. Legend Financial Advisors Inc. acquired a new position in Merck & Co., Inc. during the second quarter worth about $25,000. CBIZ Investment Advisory Services LLC lifted its position in shares of Merck & Co., Inc. by 141.7% during the 1st quarter. CBIZ Investment Advisory Services LLC now owns 377 shares of the company’s stock valued at $34,000 after acquiring an additional 221 shares during the period. Fiduciary Wealth Partners LLC purchased a new stake in shares of Merck & Co., Inc. during the 1st quarter worth approximately $48,000. MJT & Associates Financial Advisory Group Inc. acquired a new stake in shares of Merck & Co., Inc. in the 1st quarter worth approximately $48,000. Finally, Mountain Hill Investment Partners Corp. acquired a new stake in shares of Merck & Co., Inc. in the 2nd quarter worth approximately $43,000. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Analyst Upgrades and Downgrades

MRK has been the subject of several research reports. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Merck & Co., Inc. in a report on Wednesday, October 8th. Wells Fargo & Company dropped their price objective on shares of Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 30th. Berenberg Bank downgraded shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating and cut their target price for the company from $100.00 to $90.00 in a research note on Wednesday, September 17th. Morgan Stanley increased their price target on Merck & Co., Inc. from $98.00 to $100.00 and gave the stock an “equal weight” rating in a research note on Monday, November 3rd. Finally, Citigroup started coverage on shares of Merck & Co., Inc. in a report on Monday, October 13th. They set a “neutral” rating and a $95.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $104.47.

Merck & Co., Inc. Price Performance

MRK opened at $90.91 on Wednesday. Merck & Co., Inc. has a 52-week low of $73.31 and a 52-week high of $105.07. The company has a 50 day moving average of $84.76 and a two-hundred day moving average of $82.19. The company has a market cap of $225.64 billion, a P/E ratio of 14.01, a P/E/G ratio of 0.95 and a beta of 0.34. The company has a quick ratio of 1.17, a current ratio of 1.42 and a debt-to-equity ratio of 0.69.

Merck & Co., Inc. (NYSE:MRK) last posted its earnings results on Thursday, October 30th. The company reported $2.58 earnings per share for the quarter, beating the consensus estimate of $2.36 by $0.22. Merck & Co., Inc. had a net margin of 25.79% and a return on equity of 41.05%. The business had revenue of $17.28 billion for the quarter, compared to analyst estimates of $17 billion. During the same quarter in the previous year, the business posted $1.57 EPS. The business’s quarterly revenue was up 3.7% on a year-over-year basis. Merck & Co., Inc. has set its FY 2025 guidance at 8.930-8.980 EPS. On average, analysts expect that Merck & Co., Inc. will post 9.01 earnings per share for the current year.

Insider Activity at Merck & Co., Inc.

In other Merck & Co., Inc. news, EVP David Michael Williams sold 8,614 shares of the business’s stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $83.59, for a total transaction of $720,044.26. Following the transaction, the executive vice president owned 24,578 shares in the company, valued at $2,054,475.02. The trade was a 25.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.13% of the stock is currently owned by corporate insiders.

Merck & Co., Inc. Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.